ArticleScientific reports2025
Subtractive proteomics and molecular docking identify therapeutic targets and drug candidates in drug resistant Klebsiella Michiganensis THO-011.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Computational systems immunology and multi-scale modeling for the design of a Multi-Epitope Vaccine (MEV) against emerging multidrug-resistant Klebsiella michiganensis.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Subtractive Proteomics-Based Prioritization of Drug Targets in Enterococcus faecalis V583 and Structure-Based Identification of Plant-Derived Inhibitors Targeting Alanine Racemase: A High Priority Target.Molecular biotechnology · 2026Article
- A proteome-driven strategy to discover novel therapeutic targets in Orientia tsutsugamushi.Antonie van Leeuwenhoek · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Klebsiella michiganensis, an emerging multidrug-resistant pathogen, poses a significant public health threat. This study employed subtractive genomics to identify potential therapeutic targets in K. michiganensis THO-011. From 4,024 predicted open reading frames, we identified non-redundant, human non-homologous proteins and analyzed them for essentiality, subcellular localization, and metabolic pathway involvement. Two promising druggable targets, WP_004097788.1 and WP_219541799, vital for bacterial survival, were identified. Using AlphaFold-predicted structures, virtual screening of 10,000 natural compounds from the LOTUS database, alongside DrugBank controls, identified LTS0037797 and LTS0037810 as top inhibitors. Glide Gscores ranked these compounds, with validation via MM-GBSA binding energy and molecular dynamics simulations confirming their stability and binding efficacy. These findings highlight novel therapeutic strategies against K. michiganensis, with further in vitro studies necessary to advance these inhibitors to clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.